Reglan Tardive Dyskinesia Settlement: Understanding the Statute of Limitations in New York

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medication risks and benefits. In this tradition, patients and healthcare providers rely on clear, accessible guidance to navigate treatment decisions. The legacy of such communication emphasizes awareness of potential adverse effects while maintaining a balanced perspective on therapeutic necessity. Within this framework, a specific concern has emerged regarding prolonged use of certain medications in occupational settings. Reglan, a drug commonly prescribed for gastrointestinal disorders, has been associated with a risk of tardive dyskinesia—a movement disorder that may develop after extended exposure. For individuals in New York who have taken Reglan, particularly in contexts where medication adherence is influenced by work-related stress or shift schedules, understanding the legal implications becomes critical. The transition from general health awareness to occupational exposure concern requires recognizing that workplace factors can affect both medication use patterns and the timing of symptom recognition. Employees in high-demand industries may delay seeking medical attention for movement abnormalities, potentially impacting their ability to file claims within the statute of limitations. This pivot underscores the need for targeted education that bridges general health literacy with occupation-specific risk awareness, ensuring that workers understand their rights and the temporal constraints on legal recourse.

Medical Evidence: Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux (4 to 12 weeks) and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, a significant and well-documented risk associated with Reglan is tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, highlighting that the risk of developing TD increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning underscores the importance of using Reglan for the shortest duration necessary and periodically reassessing the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD typically involves orofacial movements such as lip smacking, puckering, or grimacing, as well as choreiform movements of the limbs or trunk. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide. The mechanistic pathway linking Reglan to TD involves its action as a dopamine D2 receptor antagonist in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. This risk is particularly concerning because TD may be irreversible even after discontinuation of the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and immediate discontinuation is recommended if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Risk Context and Legal Implications for New York Patients

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a critical issue. The FDA boxed warning clearly states that metoclopramide can cause TD, and that the risk increases with duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients may have been prescribed Reglan for extended periods beyond the recommended 12-week limit, particularly for off-label uses or chronic conditions. This prolonged exposure elevates the risk of developing TD, and the warning may not have been adequately communicated to all patients or prescribers. The label also notes that Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates early detection and intervention. For patients affected by TD after Reglan use, settlement-related considerations are relevant. Legal claims often hinge on the timeline between exposure and documented harm, as well as the adequacy of warnings provided by the manufacturer. In New York, the statute of limitations for personal injury claims generally requires filing within three years of the date of injury or discovery of the injury. For TD, this may be challenging because symptoms can develop insidiously and may not be immediately recognized as drug-related. The boxed warning emphasizes that TD can occur even after short-term use, but the risk is higher with longer treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after prolonged Reglan use may have a stronger case if they can demonstrate that the manufacturer failed to provide sufficient warnings about the risk of long-term therapy. Settlements in Reglan-related TD cases often consider factors such as the severity of the movement disorder, the duration of Reglan use, and whether the patient was informed of the risk. The FDA label explicitly states that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), and that for diabetic gastroparesis, total treatment duration should not exceed 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Deviations from these guidelines may support claims of inadequate warning or improper prescribing. In summary, the medical evidence clearly establishes a causal link between Reglan and TD, with risk increasing with longer use. The FDA boxed warning provides a strong basis for patient awareness, but gaps in communication may have led to harm. For New York patients, the statute of limitations is a key factor in pursuing settlement, and the timeline from exposure to documented TD symptoms is critical. Legal and medical professionals should carefully evaluate the duration of Reglan therapy, the presence of adequate warnings, and the onset of TD symptoms to determine eligibility for compensation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in New York?

In New York, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, generally requires filing within three years from the date of injury or discovery of the injury. Because TD symptoms can develop gradually, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that their condition was caused by Reglan. It is crucial to consult with an attorney promptly to avoid missing the deadline.

How does the FDA boxed warning for Reglan affect tardive dyskinesia settlements?

The FDA boxed warning for Reglan explicitly states that metoclopramide can cause tardive dyskinesia, with risk increasing with duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning provides strong evidence that the manufacturer was aware of the risk. If a patient was prescribed Reglan for longer than recommended or was not adequately warned, this may support a claim for inadequate warning or failure to communicate risks, potentially strengthening settlement negotiations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Reglan (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.